CSPC Pharmaceutical Group Limited: Business Overview, Financials & Competitive Analysis
CSPC Pharmaceutical Group Limited scores 7/10 on the AskCyborg Cyborg Score (Strong). Established Chinese pharma leader with diversified portfolio, growing profitability, and strategic global partnerships positioned for sustained value creation. CSPC demonstrates solid fundamentals with increasing profitability (92.93% net income growth in latest half-year), attractive dividend yield (5.44%), and broad portfolio diversification across 1,000+ products in seven therapeutic areas. Market.
What is CSPC Pharmaceutical Group Limited's industry? CSPC Pharmaceutical Group Limited (cspc.com.hk) operates in Pharmaceuticals & Biotechnology. AskCyborg classifies CSPC Pharmaceutical Group Limited under Pharmaceuticals & Biotechnology in its company registry.
CSPC Pharmaceutical Group Limited is a leading Chinese pharmaceutical company listed on the Hong Kong Stock Exchange since 1994 and a constituent of the Hang Seng Index. The company manufactures and sells a diverse po...
Cyborg Score thesis
Established Chinese pharma leader with diversified portfolio, growing profitability, and strategic global partnerships positioned...
Read the full analyst-debate transcript →Get the Latest CSPC Pharmaceutical Group Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCSPC Pharmaceutical Group Limited Overview
Pro stress-test →CSPC Pharmaceutical Group Limited is a leading Chinese pharmaceutical company listed on the Hong Kong Stock Exchange since 1994 and a constituent of the Hang Seng Index. The company manufactures and sells a diverse portfolio of pharmaceutical products across finished drugs, bulk products (vitamin C and antibiotics), and functional foods with operations spanning mainland China, Asia, Europe, and North America.
Strategic Profile
Pro stress-test →CSPC operates with innovative drugs as its core strategy, focusing on therapeutic areas including nervous system diseases, oncology, anti-infectives, and cardiovascular disease. The company maintains strong competitive positioning through vertical integration—manufacturing both active pharmaceutical ingredients (APIs) and formulations—and has established strategic collaborations including one with AstraZeneca for obesity and type 2 diabetes treatments.
Competitive Landscape
Pro stress-test →CSPC competes within China's pharmaceutical sector against other large domestic manufacturers and multinational companies. Key competitive advantages include extensive product portfolio spanning 1,000+ medications, vertical integration capabilities, and first-mover position among Chinese pharma in the Hang Seng Index. The company differentiates through therapeutic breadth and API manufacturing scale.
Industry Context
CSPC Pharmaceutical Group Limited operates in Pharmaceuticals & Biotechnology.
Key facts
Founded: 1992 · Headquarters: Shijiazhuang, China · Employees: 21,400 · Revenue: Not disclosed in latest data · Market cap: HKD 105.09B (~USD 13.4B)